| Product Code: ETC8673818 | Publication Date: Sep 2024 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
In 2024, Norway continued to import non-alcoholic steatohepatitis (NASH) biomarkers primarily from Denmark, Ireland, UK, USA, and Germany. The market concentration, as measured by the HHI, remained at a moderate level. Despite a negative compound annual growth rate (CAGR) from 2020 to 2024, there was a notable growth rate of 12.73% from 2023 to 2024, indicating a potential turnaround in the market dynamics. This suggests that Norway`s demand for NASH biomarkers is evolving, with an increasing interest in advanced diagnostic tools from key exporting countries.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Overview |
3.1 Norway Country Macro Economic Indicators |
3.2 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, 2021 & 2031F |
3.3 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market - Industry Life Cycle |
3.4 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market - Porter's Five Forces |
3.5 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume Share, By Biomarker Type, 2021 & 2031F |
3.6 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of non-alcoholic steatohepatitis (NASH) in Norway |
4.2.2 Growing awareness about the importance of early diagnosis and monitoring of NASH |
4.2.3 Technological advancements in biomarker development for NASH |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for approval of biomarkers |
4.3.2 Limited reimbursement policies for NASH biomarker tests |
5 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Trends |
6 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, By Types |
6.1 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, By Biomarker Type |
6.1.1 Overview and Analysis |
6.1.2 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, By Biomarker Type, 2021- 2031F |
6.1.3 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, By Serum Biomarkers, 2021- 2031F |
6.1.4 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, By Biomarker Panels, 2021- 2031F |
6.1.5 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, By Fibrosis Biomarkers, 2021- 2031F |
6.1.6 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, By Imaging Biomarkers, 2021- 2031F |
6.1.7 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, By End User |
6.2.1 Overview and Analysis |
6.2.2 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.2.3 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, By Diagnostic Centers, 2021- 2031F |
6.2.4 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenues & Volume, By Others, 2021- 2031F |
7 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Import-Export Trade Statistics |
7.1 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Export to Major Countries |
7.2 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Imports from Major Countries |
8 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Key Performance Indicators |
8.1 Number of research studies focusing on NASH biomarkers in Norway |
8.2 Adoption rate of NASH biomarker tests by healthcare providers |
8.3 Investment in RD for innovative NASH biomarkers |
8.4 Number of collaborations between diagnostic companies and research institutions for NASH biomarker development |
9 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market - Opportunity Assessment |
9.1 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Opportunity Assessment, By Biomarker Type, 2021 & 2031F |
9.2 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market - Competitive Landscape |
10.1 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenue Share, By Companies, 2024 |
10.2 Norway Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |